Decision Memo

GLP-1 pharmacy index

Record the team verdict, rationale, and reviewer leans locally, then print or share a source-anchored memo.

Markdown export

Agent and email version.

# Decision Memo: GLP-1 pharmacy index

Full report: https://ideanavigatorai.com/ideas/glp-1-pharmacy-index/
Recorded: Not recorded

## Decision
- Team verdict: Park
- Validation verdict: Research (51/100)
- Confidence: 55%
- Recommendation: Keep this parked until the team has evidence for the next validation step: Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a 'find my dose cheapest near me' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.

## Team rationale
No team rationale recorded yet.

## Reviewers
- No named reviewers recorded.

## Source anchors
- Buyer: Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.
- Market: US GLP-1 access and pricing data — a real-time index of brand-name GLP-1 (Ozempic, Wegovy, Zepbound, Mounjaro) stock, dose availability, and cash-pay price across pharmacies and manufacturer direct channels.
- Problem: Even after the FDA declared the GLP-1 shortages resolved (tirzepatide Dec 2024, semaglutide Feb 2025), patients still hit localized stockouts of specific doses and face cash prices that swing from roughly $199 to $1,000+ per month depending on whether they buy via LillyDirect, NovoCare, Costco, Walmart, or a retail pharmacy. There is no neutral, normalized, machine-readable index that tracks dose-level availability and the cheapest legitimate price for a given drug, dose, and ZIP at a point in time.
- Thesis: GLP-1 pharmacy index should be tested as a narrow first-win workflow for Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed..
- Source: https://www.drugtopics.com/view/glp-1-no-longer-on-fda-s-drug-shortage-list
- Source: https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- Source: https://www.cnbc.com/2024/05/29/ro-launches-glp-1-supply-tracker-to-help-patients-navigate-shortages.html
- Source: https://www.cnbc.com/2025/12/01/eli-lilly-prices-zepbound-weight-loss-drug-vials.html
- Source: https://www.shrm.org/topics-tools/news/benefits-compensation/glp1-drugs-employers-annual-claims-may-2025

## Validation rubric
Rubric version: INAV-VALIDATION-2026-06-04

### Demand signal - 5.9/10 (24% weight)
Demand looks thin because the report has 4 source-backed signal(s), an editorial confidence of 55/100, and a defined buyer in US GLP-1 access and pricing data — a real-time index of brand-name GLP-1 (Ozempic, Wegovy, Zepbound, Mounjaro) stock, dose availability, and cash-pay price across pharmacies and manufacturer direct channels..

- FDA removed tirzepatide (Mounjaro/Zepbound) from its shortage list in December 2024 and semaglutide (Ozempic/Wegovy) in February 2025, with phased 503A/503B compounding cutoff deadlines in early-to-mid 2025 — shifting the problem from blanket shortage to localized, dose-level stockouts.
- Target buyer: Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.

### Problem severity - 6.3/10 (22% weight)
Problem severity is thin when the buyer pain, customer value, and dream-outcome scores are combined.

- Even after the FDA declared the GLP-1 shortages resolved (tirzepatide Dec 2024, semaglutide Feb 2025), patients still hit localized stockouts of specific doses and face cash prices that swing from roughly $199 to $1,000+ per month depending on whether they buy via LillyDirect, NovoCare, Costco, Walmart, or a retail pharmacy. There is no neutral, normalized, machine-readable index that tracks dose-level availability and the cheapest legitimate price for a given drug, dose, and ZIP at a point in time.
- FDA removed tirzepatide (Mounjaro/Zepbound) from its shortage list in December 2024 and semaglutide (Ozempic/Wegovy) in February 2025, with phased 503A/503B compounding cutoff deadlines in early-to-mid 2025 — shifting the problem from blanket shortage to localized, dose-level stockouts.

### Willingness to pay - 5/10 (20% weight)
Willingness to pay is weak; the model has a monetization hypothesis, but it must still be proven through paid pilots or explicit pricing objections.

- Free consumer finder for top-of-funnel and crowdsourced data; revenue from a B2B availability/price API and dashboard licensed to telehealth prescribers, employers/benefits brokers, and PBMs, plus possible referral fees to legitimate pharmacy or manufacturer-direct channels (no clinical affiliate of the drug itself).
- Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a 'find my dose cheapest near me' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.

### Competitive saturation - 3.9/10 (18% weight)
Competitive room is reduced by 3 recorded alternative(s); the wedge must stay narrow and differentiated.

- Recorded alternative: Ro GLP-1 Supply Tracker
- Competitive score rewards a narrow wedge, not absence of research.

### Feasibility - 4/10 (16% weight)
Feasibility is weak for a high build if the MVP is limited to the first measurable workflow.

- Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a 'find my dose cheapest near me' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.
- Pharmacy stock data is not openly published — chains like CVS and Walgreens expose availability only in their own apps, so the index must rely on crowdsourced and scraped signals that can be stale, incomplete, or blocked by terms of service.

## Market gap
Underserved segments:
- Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed. who still run the workflow in spreadsheets, generic docs, email, or chat threads.
- Small teams in US GLP-1 access and pricing data — a real-time index of brand-name GLP-1 (Ozempic, Wegovy, Zepbound, Mounjaro) stock, dose availability, and cash-pay price across pharmacies and manufacturer direct channels. that feel the pain weekly but are too narrow for broad incumbents.
- New adopters who need guided proof before committing to a larger platform.

Feature gaps:
- A narrow workflow that reaches value without configuration-heavy onboarding.
- A buyer-facing proof artifact that shows time saved, risk reduced, or communication improved.
- A handoff path from manual concierge service to repeatable software.

Differentiation levers:
- Use specificity as the wedge: one buyer, one workflow, one measurable result.
- Show proof earlier than broad competitors with before-and-after examples and small pilot data.
- Keep implementation lighter than incumbent suites or generic AI assistants.

## Roast and risks
Promising enough to test, not strong enough to build broadly.

Blind spots:
- Pharmacy stock data is not openly published — chains like CVS and Walgreens expose availability only in their own apps, so the index must rely on crowdsourced and scraped signals that can be stale, incomplete, or blocked by terms of service.
- A broad AI assistant can flatten differentiation unless the wedge is painfully specific.
- The first release can become a generic dashboard if the job is not named tightly.

Hard questions:
- Who wakes up already trying to solve this?
- What do they stop paying for or stop doing when this works?
- What proof would make a skeptical buyer trust it in one screen?
- What is the smallest paid version of this idea?

## Kill criteria
- Fewer than five qualified buyers agree to discuss the workflow after targeted outreach.
- No buyer can name a current cost in time, money, risk, or reputation.
- The first demo does not produce a clear next step, paid pilot, or specific objection.

## Offer ladder
- **Lead magnet (Free)**: Glp-1 Pharmacy Index checklist Goal: Capture qualified leads and learn the buyer's exact language. Value: Helps Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed. audit the painful workflow before buying software.
- **Frontend offer ($19-$99)**: Concierge review or paid template Goal: Validate urgency, workflow fit, and willingness to pay. Value: Delivers the first useful output manually before automation is trusted.
- **Core offer ($49-$499/month)**: GLP-1 pharmacy index focused SaaS Goal: Create the recurring revenue product after the narrow wedge survives tests. Value: Turns the recurring manual workflow into a repeatable product loop.
- **Continuity ($99-$1,000/year add-on)**: Monitoring, benchmarks, and monthly reporting Goal: Increase retention and make the product part of a routine. Value: Keeps the buyer engaged with ongoing proof, saved time, or reduced risk.
- **Backend offer (Custom)**: Done-with-you setup, agency, or team rollout Goal: Capture higher-value accounts once the productized wedge is proven. Value: Adds implementation help, integrations, and workflow migration.

Print-ready memo

Decision Memo: GLP-1 pharmacy index

Team verdict: Park
Validation verdict: Research / 51/100
Confidence: 55%
Recorded: Not recorded

Recommendation

Keep this parked until the team has evidence for the next validation step: Within 60 days, build a single-metro crowdsourced stock + cash-price tracker for the four brand GLP-1s and run a paid landing-page test to two buyer segments: a 'find my dose cheapest near me' consumer page, and a B2B page pitching the normalized availability/price API to telehealth and employer-benefits teams. Validate if at least 200 consumer stock reports are submitted in one metro and at least two B2B prospects sign a paid pilot or LOI for the feed.

Team rationale

No team rationale recorded yet.

Reviewers

No named reviewers recorded.

Source anchors

Buyer: Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed.
Market: US GLP-1 access and pricing data — a real-time index of brand-name GLP-1 (Ozempic, Wegovy, Zepbound, Mounjaro) stock, dose availability, and cash-pay price across pharmacies and manufacturer direct channels.
Problem: Even after the FDA declared the GLP-1 shortages resolved (tirzepatide Dec 2024, semaglutide Feb 2025), patients still hit localized stockouts of specific doses and face cash prices that swing from roughly $199 to $1,000+ per month depending on whether they buy via LillyDirect, NovoCare, Costco, Walmart, or a retail pharmacy. There is no neutral, normalized, machine-readable index that tracks dose-level availability and the cheapest legitimate price for a given drug, dose, and ZIP at a point in time.
Thesis: GLP-1 pharmacy index should be tested as a narrow first-win workflow for Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed..

Validation rubric

Demand signal

24% weight

5.9/10

Demand looks thin because the report has 4 source-backed signal(s), an editorial confidence of 55/100, and a defined buyer in US GLP-1 access and pricing data — a real-time index of brand-name GLP-1 (Ozempic, Wegovy, Zepbound, Mounjaro) stock, dose availability, and cash-pay price across pharmacies and manufacturer direct channels..

Problem severity

22% weight

6.3/10

Problem severity is thin when the buyer pain, customer value, and dream-outcome scores are combined.

Willingness to pay

20% weight

5/10

Willingness to pay is weak; the model has a monetization hypothesis, but it must still be proven through paid pilots or explicit pricing objections.

Competitive saturation

18% weight

3.9/10

Competitive room is reduced by 3 recorded alternative(s); the wedge must stay narrow and differentiated.

Feasibility

16% weight

4/10

Feasibility is weak for a high build if the MVP is limited to the first measurable workflow.

Market gap

Underserved segments

Two-sided: consumers/patients (free find-in-stock and cheapest-cash finder) plus paying B2B buyers — telehealth prescribers, employer benefits teams, and PBMs/brokers who license the availability and price feed. who still run the workflow in spreadsheets, generic docs, email, or chat threads.
Small teams in US GLP-1 access and pricing data — a real-time index of brand-name GLP-1 (Ozempic, Wegovy, Zepbound, Mounjaro) stock, dose availability, and cash-pay price across pharmacies and manufacturer direct channels. that feel the pain weekly but are too narrow for broad incumbents.
New adopters who need guided proof before committing to a larger platform.

Feature gaps

A narrow workflow that reaches value without configuration-heavy onboarding.
A buyer-facing proof artifact that shows time saved, risk reduced, or communication improved.
A handoff path from manual concierge service to repeatable software.

Differentiation levers

Use specificity as the wedge: one buyer, one workflow, one measurable result.
Show proof earlier than broad competitors with before-and-after examples and small pilot data.
Keep implementation lighter than incumbent suites or generic AI assistants.

Roast and risks

Promising enough to test, not strong enough to build broadly.

Blind spots

Pharmacy stock data is not openly published — chains like CVS and Walgreens expose availability only in their own apps, so the index must rely on crowdsourced and scraped signals that can be stale, incomplete, or blocked by terms of service.
A broad AI assistant can flatten differentiation unless the wedge is painfully specific.
The first release can become a generic dashboard if the job is not named tightly.

Hard questions

Who wakes up already trying to solve this?
What do they stop paying for or stop doing when this works?
What proof would make a skeptical buyer trust it in one screen?
What is the smallest paid version of this idea?

Kill criteria

Fewer than five qualified buyers agree to discuss the workflow after targeted outreach.
No buyer can name a current cost in time, money, risk, or reputation.
The first demo does not produce a clear next step, paid pilot, or specific objection.

Offer ladder

Lead magnet